Direxion Daily Pharmaceutical & Medical Bull 3X ETF

PILL · ETF

$13.90−$1.18 (−7.82%)TodayMarket closed ·
Prev close $15.08

About PILL

PILL was created on 2017-11-15 by Direxion. The fund's investment portfolio concentrates primarily on health care equity. PILL provides 3x daily exposure to a modified equal-weighted index of pharmaceutical companies in the US.

Issuer
Direxion
Tracks
S&P Pharmaceuticals Select Industry
Expense ratio
0.98%
Assets under management
$15.52M
Inception
Nov 15, 2017
Asset class
Equity

PILL key statistics

Market cap
0
Price-earnings ratio
0.00
Average volume
46.37K
Volume
38.23K
Open price
$15.00
High today
$15.00
Low today
$13.68
52 Week high
$24.15
52 Week low
$7.75

Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) at a glance

Direxion Daily Pharmaceutical & Medical Bull 3X ETF (PILL) last traded at $13.90, with a market cap of 0 and a price-to-earnings ratio of 0.00.

Today the fund has traded between $13.68 and $15.00. The current price is 1.6% above the day's low and 7.3% below its high.

Volume so far is 38.23K shares, in line with the average of 46.37K shares a day.

Over the past year Direxion Daily Pharmaceutical & Medical Bull 3X ETF has ranged from $7.75 to $24.15, and now sits 38% of the way up that range.

PILL news

  • Rishabh Mishra

    Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'

  • Rishabh Mishra

    Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'

  • Rishabh Mishra

    Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms

  • Rishabh Mishra

    Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies

  • Rishabh Mishra

    Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.